Company news

Bionxt Solutions Inc (CSE:BNXT) news

Bionxt Solutions Inc news releases on 6ix. Latest, Sep 8, 2026: BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation…

Bionxt Solutions Inc (CSE:BNXT) news

Press releases & updates

BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study

BioNxt Solutions Inc. Announces Closing of Extension of Convertible Debentures and Issuance of Warrants

BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline

BioNxt Solutions Announces Option Grants

BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway

BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption

BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF

BioNxt Announces Non-Brokered Private Placement of Units Pursuant to the Listed Issuer Exemption

BioNxt Solutions Inc. Announces Extension of Convertible Debentures and Issuance of Warrants

BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development

BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum

BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)

BioNxt : Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries

BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy

BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform

BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe

BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis

BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery

BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion

BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS)

BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF

Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies

BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia

BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments

BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform

BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies

BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization

BioNxt Enters the Final Stretch Before Human Trials for Next-Generation MS Drug

BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study

BioNxt : Completes “Fast-Track” US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis

BioNxt Solutions Provides Update To Annual General Meeting Matters Due To Canadian Postal Strike And IR Activities

BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis

BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform

BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization

BioNxt Solutions Announces Closing of Shares for Debt Settlement

Terry Lynch Continues as Capital Markets Advisor and BioNxt Retains Investor Relations Professionals

BioNxt : Advances Semaglutide Oral Dissolvable Film (ODF) Program with Successful Proof-of-Concept and Prototype Development

BioNxt Advances Semaglutide Oral Dissolvable Film (ODF) Program with Successful Proof-of-Concept and Prototype Development

BioNxt Announces Shares for Debt Settlement

BioNxt Solutions Completes Up-Listing to The OTCQB Market

Semaglutide API Delivery Enables Start of Lab-Scale ODF Development at BioNxt

Promotional Activity Engagements

BioNxt Fast-Tracks U.S. Patent for MS Drug and Secures Broad Platform IP Covering Autoimmune Neurology Pipeline

BioNxt Solutions Announces Closing of Final Tranche of Oversubscribed Convertible Debenture Unit Private Placement

BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment

BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement

BioNxt Delivers Positive Results in Patented Cladribine Sublingual Thin-Film Program and Completes Successful Formulation

BioNxt Solutions Announces Convertible Debenture Unit Private Placement

BioNxt : Introduces Targeted Chemotherapy Drug Delivery Platform for Precision Oncology

BioNxt Solutions Introduces Targeted Chemotherapy Drug Delivery Platform for Precision Oncology